MedTrace Logo

Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer

NCT00129974 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-06-16

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer. The second purpose is to see if the side effects appear better than what is expected with standard chemotherapy.

Conditions

  • Carcinoma, Small Cell

Interventions

DRUG

pemetrexed and gemcitabine

Sponsors & Collaborators

Principal Investigators

  • John R Goffin, MD FRCPC · Tufts Medical Center

  • John McCann, MD · Baystate Medical Center

  • Walter A Kagan, MD PhD · Commonwealth Hematology/Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00129974 on ClinicalTrials.gov